Test Banner Test Banner

Workstream 2


This is the clinical biochemistry workstream which focuses on rapid identification of protein biomarkers with the appropriate clinical characteristics to justify evaluation in the health service. 

One of the remits of workstream 2 is the creation of a sample banking system for collecting and storing patient samples and relevant clinical data from large numbers of patients. This will allow the immediate testing of potential new biomarkers, now and in the future. The most promising biomarkers would then go on to full clinical trials to analyse whether patients and the NHS would benefit from their use.

The Leeds NIHR Biomarker Research Tissue Bank is storing the following sample types, which are collected from multiple centres around the UK:

  • Serum samples from patients with liver disease
  • Serum, plasma, urine, buffy coat, FFPE and fresh tissue, cross-sectionally and longitudinally from renal cell carcinoma patients
  • Plasma, serum and urine samples from patients prior to and following renal transplantation
  • Plasma serum and urine from healthy volunteers
  • Surplus diagnostic samples (serum/plasma/urine/CSF) containing interfering substances

Full clinical data is collected using Case Report Forms. For further information about collaborative access to these samples for research, please email rtb@leeds.ac.uk.

Progress to Date

Renal Cell Carcinoma (RCC)

RCC recruitment is now closed. The study has recruited 708 participants in total. The graph below shows RCC accrual by centre.

RCC

Renal Transplant (RT)

The RT study has recruited 501 participants from 10 centres. The graph below shows RT accrual by centre to 17th February 2015.


RT Accrual

Healthy Volunteer

Healthy volunteer recruitment closed at the end of June 2014, with a total of 199  participants recruited. The graph below shows healthy volunteer accrual by centre to 30th June 2014.


HV Accrual

Liver Disease

The Leeds NIHR Biomarker Research Tissue Bank is also collecting serum samples from patients with liver disease, participating in the ELUCIDATE trial. The samples are collected from the following participating centres:

  • University College London Hospitals NHS Foundation Trust (PIs – Prof William Rosenberg & Dr Sudeep Tanwar)
  • Royal Free London NHS Foundation Trust (PI – Dr Douglas Thorburn)
  • Royal Devon and Exeter NHS Foundation Trust (PI – Dr John Christie)
  • Royal Bournemouth and Christchurch Hospitals NHS Foundation Trust (PI – Dr Earl Williams)
  • King’s College Hospital NHS Foundation Trust (PIs – Dr Abid Suddle & Dr Kosh Agarwal)
  • The Royal Liverpool and Broadgreen University Hospitals NHS Trust (PI – Dr Paul Richardson)
  • University Hospital Southampton NHS Foundation Trust (PI – Dr Mark Wright)
  • Hampshire Hospitals NHS Foundation Trust, Basingstoke & North Hampshire (PI – Dr John Ramage)
  • Sheffield Teaching Hospitals NHS Foundation Trust (PI – Dr Dermot Gleeson)
  • Barts & The London NHS Trust of the Royal London Hospital (PI – Dr Paul Kooner)
  • The Leeds Teaching Hospitals NHS Trust (PI – Dr Mark Aldersley)
  • Plymouth Hospitals NHS Trust (PI – Dr Usama Warshow)
  • The Newcastle upon Tyne Hospitals NHS Foundation Trust (PI – Dr Quentin Anstee)
  • Hull and East Yorkshire Hospitals NHS Trust (PI - Dr George Abouda)
  • The Rotherham NHS Foundation Trust (PI – Dr Barbara Hoeroldt)
  • Blackpool Teaching Hospitals NHS Foundation Trust (PI – Dr Christopher Shorrock)
  • Nottingham University Hospitals NHS Trust (PI – Dr Stephen Ryder)
  • South Devon Healthcare NHS Foundation Trust (PI – Dr Keith George)
  • East Lancashire Hospitals NHS Trust (PI – Dr Yogi Reddy)
  • Lewisham Healthcare NHS Trust (PI – Dr Raj Srirajaskanthan)
  • South Tees Hospitals NHS Foundation Trust (PI - Dr Helen Dallal)
  • Wrightington, Wigan and Leigh NHS Foundation Turst (PI - Dr Richard Keld)
  • Portsmouth Hospitals NHS Trust (PI – Dr Andrew Fowell)
  • Warrington and Halton Hospitals NHS Foundation Trust (PI – Dr Sundaramoorthy Bharathi)
  • Chelsea & Westminster Hospital NHS Foundation Trust (PI – Dr Matthew Foxton)
  • University Hospitals of Morecambe Bay NHS Foundation Trust (PI – Dr Andrew Higham)
  • The Princess Alexandra Hospital NHS Trust (PI – Dr Deb Ghosh)
  • Kingston Hospital NHS Foundation Trust (PI – Dr Neil Galletly)
  • Lancashire Teaching Hospitals NHS Foundation Trust (PI - Philip Shields)
  • University Hospitals Bristol NHS Foundation Trust (PI – Dr Peter Collins)
  • Hywel Dda Local Health Board (PI – Dr Russell Canavan)
  • Brighton and Sussex University Hospitals NHS Trust (PI – Dr Sumita Verma)
  • Bradford Teaching Hospitals NHS Foundation Trust (PI – Dr Sulleman Moreea)
  • University Hospitals Birmingham NHS Foundation Trust (PI – Dr Phillip Newsome)
  • Abertawe Bro Morgannwg University Local Health Board (PI – Dr Chin Lye Ch'ng)
  • County Durham and Darlington NHS Foundation Trust (PI - Dr Sushma Saksena)
  • Hampshire Hospitals NHS Foundation Trust, Royal Hampshire County Hospital (PI – Dr John Ramage)

 

Many thanks to all of the patients who have consented to participate and to the staff at each site who are contributing to these studies!


Recent Publications:

  1. Welberry Smith M, Zougman A, Cairns DA, Wilson M, Wind T, Wood SL, Thompson D, Messenger MP, Mooney A, Selby PJ, Lewington AJP, Banks RE. Proteomic identification of serum aminoacylase-1 as a novel biomarker for delayed graft function after renal transplantation and association with long-term outcome. Kidney International. 2013; 84: 1214 - 1225.
  2. Kift RL, Messenger MP, Wind TC, Hepburn S, Wilson M, Thompson D, Welberry Smith M, Sturgeon C, Lewington AJ, Selby PJ, Banks RE. A comparison of the analytical performance of five commercially available assays for neutrophil gelatinase-associated lipocalin using urine.  Annals of Clinical Biochemistry. 2013; 50(3): 236-244.
  3. Sim SH, Messenger MP, Gregory WM, Wind TC, Vasudev NS, Cartledge J, Thompson D, Selby PJ, Banks RE. Prognostic utility of pre-operative circulating osteopontin, carbonic anhydrase IX and CRP in renal cell carcinoma. British Journal of Cancer. 2012; 107: 1131-1137.
  4. Wind TC, Messenger MP, Thompson D, Selby P, Banks RE. Measuring carbonic anhydrase IX as a hypoxia biomarker: differences in concentrations in serum and plasma using commercial enzyme-linked immunosorbent assay due to influences of metal ions. Annals of Clinical Biochemistry. 2011; 48: 112-120.





This website presents independent research funded by the National Institute for Health Research (NIHR) under its Programme Grants for Applied Research Programme (RP-PG-0707-10101: Evaluating the benefits for patients and the NHS of new and existing biological fluid biomarkers in liver and renal disease)

The views and opinions expressed by the authors of this website are those of the authors and do not necessarily reflect those of the NHS, the NIHR or the Department of Health.

 
The Leeds Teaching Hospital NHS Trust 2014